Morgan Stanley raised the firm’s price target on UnitedHealth (UNH) to $411 from $395 and keeps an Overweight rating on the shares. The firm notes the company’s 2026 outlook centers on disciplined repricing, margin recovery, and Optum restructuring, with “modest” EPS growth in 2026 as a starting point and stronger performance in 2027 as MA / Optum Health recovery more meaningfully takes shape.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on UNH:
- Midday Fly By: Nvidia hits $5T market cap, Boeing takes big 777X charge
- “Watch the Valuation” Top Deutsche Bank Analyst Downgrades UnitedHealth Stock (UNH) despite Q3 Beat
- Skyworks upgraded, UnitedHealth downgraded: Wall Street’s top analyst calls
- UnitedHealth price target raised to $430 from $378 at UBS
- UnitedHealth price target raised to $408 from $286 at RBC Capital